Spirox Osake

Spirox EV/FCF

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä Spirox (3055.TW) 4.8.2026 päivämäärällä on −27,63. Edellisenä vuonna EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) oli −25,49 — muutos 8,36 % (matalampi).

EV/FCF

−27,63

YoY

8,36%

Viimeksi päivitetty:

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä Spirox on 2026 −27,63 . EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä Spirox oli 2025 −25,49 . Se laskee 8,36% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Spirox Osakeanalyysi

Mitä Spirox tekee? The Spirox Corporation is a company that was founded in 2007 and is headquartered in Menlo Park, California. The company operates in the medical technology industry and specializes in the development of products for nasal breathing. The mission of Spirox is to help people who have difficulty breathing through their nose. The company has recognized that many people have difficulty breathing through their nose due to congestion or other issues. Breathing through the mouth, however, can lead to a range of health problems such as dry mouth, sleep apnea, and respiratory infections. Therefore, Spirox has set out to develop innovative solutions to facilitate nasal breathing. Spirox's products include both implantable and non-implantable solutions. The company has a small but effective product portfolio consisting of two products: the Latera Nasal Stent and the AeroForm Nasal Stent. The Latera Nasal Stent is used to permanently open the nasal passages and facilitate breathing. The placement of the stent is a minimally invasive procedure that is typically performed on an outpatient basis. The Latera Nasal Stent is inserted and secured in the nasal wings to allow for better airflow through the nostrils. The stent is made of polydioxanone (PDO), a biocompatible polymer fiber that is absorbed by the body. Spirox's second product, the AeroForm Nasal Stent, is a non-implantable nasal stent used for temporary relief of nasal breathing. The AeroForm is a soft stent made of a flexible polymer material. It is inserted into the nasal passages and forms a gentle expansion to facilitate nasal breathing. As a company, Spirox focuses on collaboration with specialists and clinics to ensure that their products have high success rates. The company has established a partnership with the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) to advance scientific research and development in the nasal breathing industry. Spirox is led by experienced executives from the medical technology industry. The CEO, Duke Rohlen, has over 20 years of experience in leading medical technology companies such as Inspire Medical Systems and CV Ingenuity. The board team also includes Elektra Papadopoulos as Chair of the Board, who has worked at Hologic and Boston Scientific, among others. Although Spirox is a relatively small company, it has already received several awards. In 2017, the company was awarded the Red Herring Top 100 North America Award, which recognizes companies that are leading in the innovation industry. Overall, Spirox is an emerging company in the medical technology industry that offers innovative solutions to facilitate nasal breathing. Through collaboration with doctors and clinics and a focus on scientific research, the company aims to improve the success and effectiveness of its products. Spirox on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Spirox osakkeesta

Yhtiön Spirox EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) on −27,63 vuonna 2026.

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä Spirox muuttui arvosta −25,49 arvoon −27,63, mikä edustaa 8,36 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) Spirox:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EV/FCF-suhde mittaa yrityksen arvoa suhteessa vapaaseen kassavirtaan. Se heijastaa yrityksen todellista kassantuottokykyä.

Arvioidakseen EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan):n Spirox alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Spirox

Kaikki tunnusluvut — Spirox